CROSSPOINT Therapeutics, a South Korean biotech developing next-generation antibody technologies, has secured $2.38M (3.6 billion KRW) in a Pre-Series A funding round.

KUDOS Ventures and Soo Investment Capital co-led the round, with strategic investors Y-Biologics and BMI Korea also participating.

The company’s core technology, Stealth-Body, is designed to significantly reduce the side effects associated with antibody-drug conjugates (ADCs) and immuno-oncology therapies. The platform works by modifying specific regions of an antibody to block unnecessary interactions with immune cells — a technique known as Fc silencing — which allows for more targeted therapeutic action and a better safety profile compared to conventional treatments.

CROSSPOINT Therapeutics is based at the Hongcheon National Antibody Cluster, a government-supported research hub in Gangwon Province, and has leveraged its neutralizing antibody and immune antibody development centers to accelerate its pipeline. Local government support has also played a role, with Hongcheon County providing research infrastructure and administrative assistance through its job-creation industrial development program.

Hongcheon County noted that the successful fundraise demonstrates the cluster’s strength as a launchpad for biotech ventures, and reaffirmed its commitment to expanding research infrastructure and improving the living environment for researchers — with the broader ambition of establishing Hongcheon as a national hub for novel drug development.

CEO Taeuk Kim said the company plans to use the proceeds to conduct primate preliminary toxicity studies within the year, with the goal of achieving strong Therapeutic Index results — a key metric for international technology licensing — to validate the superiority of the Stealth-Body platform.